Press Releases

While splice modulation has produced some of the field's most significant successes to date, researchers are increasingly exploring direct RNA binding as a route to achieving…
Read More...

Computational technologies are reshaping RNA-targeted drug discovery, enabling researchers to identify promising therapeutic targets with greater confidence and efficiency than ever…
Read More...

The journey from RNA-targeting concept to clinical reality will be a key focus at the upcoming 9th Annual RNA-Targeted Drug Discovery & Development Summit in Boston this November.…
Read More...

Leading model-informed drug development experts to unite in Boston to explore pharmacometrics, AI, quantitative systems pharmacology, and evolving regulatory expectations The 2nd…
Read More...

With one week remaining until the 4th TRP Supply Chain & Manufacturing Summit, senior leaders from across the radiopharmaceutical industry are preparing to gather in Boston to…
Read More...

The 9th Annual RNA-Targeted Drug Discovery & Development Summit will unite the scientists, drug developers, and industry leaders advancing RNA-targeted small molecules from early…
Read More...

The World ADC Awards 2026 shortlist has been announced, recognizing the organizations, teams, technologies, and individuals driving innovation and advancing the field of antibody-drug…
Read More...

Clinical translation insights to accelerate the development of differentiated autoimmune T-cell engager therapies. Following rapid progress in the autoimmune T-cell engager field,…
Read More...

Industry leaders from Gilead Sciences, Sanofi, Eli Lilly, Takeda, Bristol Myers Squibb, Novartis and more will gather to address safety, translational predictability, biomarker strategy…
Read More...

Autoimmune T-Cell Engager Field Reaches Defining Moment as Industry Leaders Prepare to Unite in Boston Boston, MA | October 27–29, 2026 The autoimmune T-cell engager field is…
Read More...

As investment, innovation, and dealmaking continue to reshape the antibody-drug conjugate (ADC) landscape, Michael Torres, Chief Executive Officer of CrossBridge Bio, has shared his…
Read More...

Are We Asking the Right Questions in COPD Drug Development? As the industry looks beyond traditional measures such as lung function and exacerbations, a new question is emerging: What…
Read More...

The energy coming out of this year’s ATS meeting was unmistakable: respiratory medicine is entering a new era of scientific ambition, cross‑industry collaboration, and patient‑centred…
Read More...

The preliminary agenda for the 17th World ADC San Diego, taking place October 12–15, 2026, has been released, offering an exclusive first look at the scientific program for the world’s…
Read More...

Radiopharmaceuticals continue to reshape oncology strategy. Regeneron’s entry into radiopharma through its partnership with Telix investing $40M upfront across up to four oncology…
Read More...

As New Approach Methodologies (NAMs) and microphysiological systems (MPS) continue to gain momentum across drug development, the imperative facing industry scientists is increasingly…
Read More...

As antibody-drug conjugates (ADCs) continue to move into more complex payload classes and higher drug–antibody ratios, linker and conjugation chemistry remains a critical bottleneck for…
Read More...

Join the 3rd Biophysics for Drug Discovery Summit – The Countdown Is On! Biophysical methods underpin some of today’s most powerful drug discovery decisions — yet translating physical…
Read More...

Join the 5th Extrahepatic Lipid-Based Nanoparticles Delivery Summit As lipid-based therapeutics continue to advance, developers face growing pressure to deliver precise,…
Read More...

Ahead of the Investigative & Preclinical Toxicology Summit 2026, the dedicated Pre‑Conference Workshop Day is emerging as one of the most highly anticipated elements of the meeting,…
Read More...